• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526

Recent Advances in the Application of 4-methyl-3-(trifluoromethyl)pyridine (CAS: 1214344-10-1) in Chemical Biology and Pharmaceutical Research

The compound 4-methyl-3-(trifluoromethyl)pyridine (CAS: 1214344-10-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and versatile applications. This heterocyclic compound, characterized by a pyridine ring substituted with a methyl group at the 4-position and a trifluoromethyl group at the 3-position, exhibits remarkable stability and reactivity, making it a valuable building block in drug discovery and development. Recent studies have explored its potential as a key intermediate in the synthesis of novel therapeutic agents, particularly in the areas of oncology, neurology, and infectious diseases.

One of the most notable applications of 4-methyl-3-(trifluoromethyl)pyridine is its role in the development of kinase inhibitors. Kinases are critical targets in cancer therapy, and the trifluoromethyl group in this compound enhances the binding affinity and selectivity of inhibitors towards specific kinase isoforms. A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of derivatives of 4-methyl-3-(trifluoromethyl)pyridine in inhibiting aberrant kinase activity in non-small cell lung cancer (NSCLC) models. The study highlighted the compound's ability to improve pharmacokinetic properties, such as metabolic stability and oral bioavailability, which are crucial for clinical success.

In addition to its role in oncology, 4-methyl-3-(trifluoromethyl)pyridine has shown promise in the design of central nervous system (CNS) drugs. The trifluoromethyl group's lipophilicity and electron-withdrawing properties facilitate blood-brain barrier penetration, a key challenge in CNS drug development. Recent research published in ACS Chemical Neuroscience reported the synthesis of novel GABA_A receptor modulators using this compound as a core scaffold. These modulators exhibited potent anxiolytic and anticonvulsant activities in preclinical models, suggesting potential applications in treating anxiety disorders and epilepsy.

The compound's utility extends to antimicrobial drug development as well. A 2022 study in Bioorganic & Medicinal Chemistry Letters described the synthesis of 4-methyl-3-(trifluoromethyl)pyridine-based analogs with potent activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed the enhanced antibacterial activity to the compound's ability to disrupt bacterial cell membrane integrity and inhibit essential enzymes involved in bacterial metabolism. These findings underscore the potential of 4-methyl-3-(trifluoromethyl)pyridine as a versatile scaffold for addressing the global challenge of antimicrobial resistance.

Despite these promising developments, challenges remain in optimizing the synthetic routes for 4-methyl-3-(trifluoromethyl)pyridine and its derivatives. Recent advances in green chemistry have focused on reducing the environmental impact of its production, with studies exploring catalytic methods and solvent-free reactions. A 2023 review in Chemical Reviews highlighted the progress in sustainable synthesis techniques, which could pave the way for large-scale production of this valuable compound while minimizing waste and energy consumption.

In conclusion, 4-methyl-3-(trifluoromethyl)pyridine (CAS: 1214344-10-1) represents a pivotal compound in modern chemical biology and pharmaceutical research. Its unique structural features and broad applicability make it a cornerstone in the development of innovative therapeutics across multiple disease areas. Continued research into its synthetic optimization and biological mechanisms will undoubtedly yield further breakthroughs, solidifying its role in the future of drug discovery.

• 20857-46-9(3,4-Bis(trifluoromethyl)pyridine)
• 1214373-46-2(2,3,5,6-Tetrachloro-4-(trifluoromethyl)pyridine)
• 82912-41-2(3,4-bis(trifluoromethyl)-1H-Pyrrole)
• 1227598-69-7(3-(trifluoromethyl)pyridin-4-ylmethanol)
• 3796-23-4(3-(Trifluoromethyl)pyridine)
• 1803844-39-4(4-Phenyl-3-(trifluoromethyl)pyridine)
• 1805287-42-6(4-(Difluoromethyl)-3-methylpyridine)
• 1805301-95-4(3-(Difluoromethyl)-4-methylpyridine)
• 1804410-47-6(3,4-Bis(trifluoromethyl)-5-methylpyridine)
• 1060801-91-3(3-(trifluoromethyl)pyridin-4-ylmethanamine)